Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

<h4>Background</h4> <p>The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 stu...

書誌詳細
主要な著者:	Helliwell, P, Coates, L, Fitzgerald, O, Nash, P, Soriano, E, Husni, M, Hsu, M, Kanik, K, Hendrikx, T, Wu, J, Kudlacz, E
フォーマット:	Journal article
出版事項:	BioMed Central 2018

類似資料

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
著者:: Philip Helliwell, 等
出版事項: (2018-10-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
著者:: Helliwell, P, 等
出版事項: (2018)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
著者:: Nash, P, 等
出版事項: (2018)

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
著者:: Nash, P, 等
出版事項: (2018)

Janus kinase inhibitors in the treatment of psoriatic arthritis
著者:: E. Yu. Loginova, 等
出版事項: (2022-02-01)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
著者:: Coates, L, 等
出版事項: (2016)

Assessing disease activity in psoriatic arthritis: a literature review
著者:: Tucker, L, 等
出版事項: (2018)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
著者:: Miao Chen, 等
出版事項: (2020-04-01)

Sustained very low disease activity and remission in psoriatic arthritis patients
著者:: Lubrano, E, 等
出版事項: (2019)

Current concepts and unmet needs in psoriatic arthritis
著者:: Mahmood, F, 等
出版事項: (2017)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
著者:: Nash, P, 等
出版事項: (2018)

Remission in psoriatic arthritis—where are we now?
著者:: Coates, L, 等
出版事項: (2017)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
著者:: P.S. Helliwell
出版事項: (2011-09-01)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
著者:: Ennio Lubrano, 等
出版事項: (2019-08-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
著者:: Coates, LC, 等
出版事項: (2024)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
著者:: Coates, L, 等
出版事項: (2021)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
著者:: Coates, L, 等
出版事項: (2018)

Best-practice indicators in Psoriatic disease care
著者:: Helliwell, P, 等
出版事項: (2019)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
著者:: Coates, L, 等
出版事項: (2016)

What should be the primary target of "treat to target" in psoriatic arthritis?
著者:: Coates, LC, 等
出版事項: (2018)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
著者:: Peter Nash, 等
出版事項: (2018-11-01)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
著者:: Mease, P, 等
出版事項: (2018)

Psoriatic arthritis
著者:: FitzGerald, O, 等
出版事項: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
著者:: Laura C. Coates, 等
出版事項: (2021-03-01)

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
著者:: Jiao Wang, 等
出版事項: (2025-02-01)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
著者:: Coates, L, 等
出版事項: (2022)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
著者:: Soriano, ER, 等
出版事項: (2023)

Psoriatic Arthritis: A Review
著者:: Farrouq Mahmood, 等
出版事項: (2016-07-01)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
著者:: Helliwell, PS, 等
出版事項: (2021)

Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
著者:: E. E. Gubar, 等
出版事項: (2021-10-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
著者:: Laure Gossec, 等
出版事項: (2024-02-01)

How should we define disease and outcomes in axial psoriatic arthritis?
著者:: Coates, LC
出版事項: (2021)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
著者:: Vivekanantham, A, 等
出版事項: (2024)

Measuring outcomes in psoriatic arthritis
著者:: Ogdie, A, 等
出版事項: (2020)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
著者:: Vishal R. Tandon, 等
出版事項: (2022-07-01)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
著者:: Braun, J, 等
出版事項: (2023)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
著者:: Philip J. Mease, 等
出版事項: (2023-08-01)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
著者:: Yazji, SM, 等
出版事項: (2025)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
著者:: Nash, P, 等
出版事項: (2021)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
著者:: Coates, LC, 等
出版事項: (2022)